542 results on '"Kastelein, John J.P."'
Search Results
2. Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trials
3. Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
4. The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease
5. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
6. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial
7. Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model
8. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
9. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia
10. Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study
11. Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic
12. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
13. Can we revive CETP-inhibitors for the prevention of cardiovascular disease?
14. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia
15. New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4
16. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
17. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial
18. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial
19. Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses
20. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia
21. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
22. Lipoprotein(a) levels and carotid intima-media thickness in children: A 20-year follow-up study.
23. Effect of Evolocumab on Coronary Plaque Composition
24. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
25. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy
26. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
27. Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia
28. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
29. Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia
30. Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia
31. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial
32. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
33. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses
34. Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)
35. Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia
36. Children with hypercholesterolemia of unknown cause: Value of genetic risk scores
37. Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution
38. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design
39. Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia
40. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial
41. Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS
42. Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
43. Familial hypercholesterolaemia: A global call to arms
44. Moving Targets: Recent Advances in Lipid-Lowering Therapies
45. Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk
46. Screening and treatment of familial hypercholesterolemia – Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014)
47. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood
48. Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia
49. Pegozafermin for the Treatment of Severe Hypertriglyceridemia: A Randomized, Double-blind, Placebo-controlled Phase 2 Study (ENTRIGUE STUDY)
50. Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.